- Home
- XPRO vs MLYS Comparison
XPRO vs MLYS Comparison
Compare XPRO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- MLYS
- Stock Information
- Founded
- XPRO 1938
- MLYS 2019
- Country
- XPRO United States
- MLYS United States
- Employees
- XPRO N/A
- MLYS N/A
- Industry
- XPRO Oilfield Services/Equipment
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- MLYS Health Care
- Exchange
- XPRO Nasdaq
- MLYS Nasdaq
- Market Cap
- XPRO 1.0B
- MLYS 890.6M
- IPO Year
- XPRO 2013
- MLYS 2023
- Fundamental
- Price
- XPRO $10.95
- MLYS $14.52
- Analyst Decision
- XPRO Buy
- MLYS Strong Buy
- Analyst Count
- XPRO 4
- MLYS 4
- Target Price
- XPRO $12.50
- MLYS $27.00
- AVG Volume (30 Days)
- XPRO 1.5M
- MLYS 743.4K
- Earning Date
- XPRO 07-29-2025
- MLYS 08-12-2025
- Dividend Yield
- XPRO N/A
- MLYS N/A
- EPS Growth
- XPRO N/A
- MLYS N/A
- EPS
- XPRO 0.61
- MLYS N/A
- Revenue
- XPRO $1,673,283,000.00
- MLYS N/A
- Revenue This Year
- XPRO N/A
- MLYS N/A
- Revenue Next Year
- XPRO $3.97
- MLYS N/A
- P/E Ratio
- XPRO $18.04
- MLYS N/A
- Revenue Growth
- XPRO 2.67
- MLYS N/A
- 52 Week Low
- XPRO $6.70
- MLYS $8.24
- 52 Week High
- XPRO $21.57
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- XPRO 59.54
- MLYS 57.42
- Support Level
- XPRO $10.18
- MLYS $12.59
- Resistance Level
- XPRO $10.90
- MLYS $13.70
- Average True Range (ATR)
- XPRO 0.74
- MLYS 0.75
- MACD
- XPRO 0.02
- MLYS 0.11
- Stochastic Oscillator
- XPRO 49.78
- MLYS 75.39
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.